US Edition
UI Pharmaceuticals partners with MimiVax on brain cancer treatment
Summary by Corridor Business Journal
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
UI Pharmaceuticals partners with MimiVax on brain cancer treatment
UI Pharmaceuticals (UIP), a division of the University of Iowa College of Pharmacy, has partnered with New York-based MimiVax to support the manufacturing of SurVaxM — a novel immunotherapeutic vaccine designed to treat glioblastoma, one of the most aggressive forms of brain cancer — for use in clinical trials.The partnership comes amid rising cancer rates in Iowa. According to the Iowa Cancer Registry, the state had the fastest-growing cancer r…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
